



Correction: Weng et al. New International Association for the Study of Lung Cancer (IASLC) Pathology Committee Grading System for the Prognostic Outcome of Advanced Lung Adenocarcinoma. *Cancers* 2020, *12*, 3426

Ching-Fu Weng ^{1,2}, Chi-Jung Huang ^{3,4,5}, Shih-Hung Huang ⁶, Mei-Hsuan Wu ⁷, Ailun Heather Tseng ⁸, Yung-Chuan Sung ⁹, Henry Hsin-Chung Lee ^{5,10,11,*} and Thai-Yen Ling ^{2,*}

- ¹ Division of Pulmonary Medicine, Department of Internal Medicine, Hsinchu Cathay General Hospital, Hsinchu 300, Taiwan; cgh18497@cgh.org.tw
- ² Department and Graduate Institute of Pharmacology, National Taiwan University, Taipei 100, Taiwan
- ³ Medical Research Center, Cathay General Hospital, Taipei 106, Taiwan; aaronhuang@cgh.org.tw
- ⁴ Department of Biochemistry, National Defense Medical Center, Taipei 114, Taiwan
- ⁵ School of Medicine, Fu Jen Catholic University, New Taipei 242, Taiwan bivision of Bathalacry Cathory Compared Hagnital Taipei 106, Taiwan 166
- Division of Pathology, Cathay General Hospital, Taipei 106, Taiwan; ja68@cgh.org.tw
- ⁷ Teaching and Research Center, Hsinchu Cathay General Hospital, Hsinchu 300, Taiwan; markicoo@cgh.org.tw
 ⁸ Department of Biomedical Sciences and Engineering, National Control University, Taouyan, 220, Taiwan;
- Department of Biomedical Sciences and Engineering, National Central University, Taoyuan 320, Taiwan; c8500@cgh.org.tw
- ⁹ Division of Hematology/Oncology, Department of Internal Medicine, Cathay General Hospital, Taipei 106, Taiwan; cgh06496@cgh.org.tw
- ¹⁰ Department of Surgery, Hsinchu Cathay General Hospital, Hsinchu 300, Taiwan
- ¹¹ Graduate Institute of Translational and Interdisciplinary Medicine, College of Health Sciences and Technology, National Central University, Taoyuan 320, Taiwan
 - Correspondence: cgh05589@cgh.org.tw (H.H.-C.L.); tyling@ntu.edu.tw (T.-Y.L.); Tel.: +886-3-527-8999 (ext. 61346) (H.H.-C.L.); +886-2-2312-3456 (ext. 88322) (T.-Y.L.)

The authors would like to make a correction to their published paper [1]. There was a mistake in the original version of the article in Figures 1 and 2. We found that Figures 1 and 2 were misplaced in the article.

They should be replaced with the following Figures 1 and 2:

Patients with newly diagnosed non-small-cell lung carcinoma (NSCLC) between 2007/01 and 2018/12 at Cathay General Hospital (CGH) (n=1317)
Exclude: Lost follow-up or incomplete treatment (n=155) Unknown subtypes (treatment at CGH, formal pathologic report from other hospital) (n=508)
Patients diagnosed as adenocarcinoma with subsequent treatment at CGH (n=654)
Exclude: Cell block, no definite pathological subtype (n=208) Carcinoma or uncertain origin, adenosquamous, neuroendocrine (n=46) Unknown gene mutation status (n=147) Lost follow-up (n=77) Metastatic lesion without completed subtyping (n=18) Early stage (Stage 1 & II) (n=22)
Lung adenocarcinoma (LADC) pathologic report according to new grading system by the International Association for the Study of Lung Cancer (IASLC) (n=136)
Late Stage LADC patients (Stage III & IV)
Well-differentiated (n=7) Moderately differentiated (n=74) Poorly-differentiated (n=55)

Figure 1. Selection criteria for the subjects.



Citation: Weng, C.-F.; Huang, C.-J.; Huang, S.-H.; Wu, M.-H.; Tseng, A.H.; Sung, Y.-C.; Lee, H.H.-C.; Ling, T.-Y. Correction: Weng et al. New International Association for the Study of Lung Cancer (IASLC) Pathology Committee Grading System for the Prognostic Outcome of Advanced Lung Adenocarcinoma. *Cancers* 2020, *12*, 3426. *Cancers* **2021**, *13*, 4024. https://doi.org/10.3390/ cancers13164024


Received: 22 December 2020 Accepted: 23 June 2021 Published: 10 August 2021


Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).







The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original article has been updated.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

Reference

 Weng, C.-F.; Huang, C.-J.; Huang, S.-H.; Wu, M.-H.; Tseng, A.H.; Sung, Y.-C.; Lee, H.H.-C.; Ling, T.-Y. New International Association for the Study of Lung Cancer (IASLC) Pathology Committee Grading System for the Prognostic Outcome of Advanced Lung Adenocarcinoma. *Cancers* 2020, *12*, 3426. [CrossRef] [PubMed]